Table 5.
Excess risk and standardised incidence ratios of urogenital, colorectal, and neurological cancers in 75 983 patients with a first diagnosis of acute urinary retention
| Cancer site | Follow-up period | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 to <3 months | 3 to <12 months | 1 to 5 years | |||||||||
| O/E | Excess risk per 1000 PY (95% CI) | SIR (95% CI) | O/E | Excess risk per 1000 PY (95% CI) | SIR (95% CI) | O/E | Excess risk per 1000 PY (95% CI) | SIR (95% CI) | |||
| Urinary tract: | 1025/49 | 56 (54 to 58) | 21.1 (19.9 to 22.5) | 354/127 | 5 (4 to 6) | 2.8 (2.5 to 3.1) | 497/454 | 0 (0 to 1) | 1.1 (1.0 to 1.2) | ||
| Women | 114/3 | 36 (32 to 39) | 40.5 (33.4 to 48.7) | 32/8 | 3 (2 to 4) | 4.2 (2.9 to 5.9) | 52/28 | 1 (0 to 2) | 1.9 (1.4 to 2.5) | ||
| Men | 911/46 | 61 (59 to 63) | 19.9 (18.7 to 21.3) | 322/119 | 5 (5 to 6) | 2.7 (2.4 to 3.0) | 445/426 | 0 (−1 to 1) | 1.0 (1.0 to 1.2) | ||
| Bladder (invasive cancer): | 434/20 | 24 (23 to 25) | 22.2 (20.1 to 24.3) | 149/51 | 2 (2 to 3) | 2.9 (2.5 to 3.4) | 228/181 | 0 (0 to 1) | 1.3 (1.1 to 1.4) | ||
| Women | 62/1 | 20 (17 to 22) | 63.2 (48.5 to 81.1) | 14/3 | 1 (1 to 2) | 5.3 (2.9 to 8.9) | 29/10 | 1 (0 to 1) | 3.0 (2.0 to 4.4) | ||
| Men | 372/19 | 25 (23 to 26) | 20.0 (18.0 to 22.1) | 135/48 | 2 (2 to 3) | 2.8 (2.4 to 3.3) | 199/171 | 0 (0 to 1) | 1.2 (1.0 to 1.3) | ||
| Bladder (non-invasive cancer): | 413/18 | 23 (22 to 24) | 22.4 (20.3 to 24.7) | 129/48 | 2 (1 to 2) | 2.7 (2.2 to 3.2) | 140/172 | 0 (−1 to 0) | 0.8 (0.7 to 1.0) | ||
| Women | 30/1 | 9 (8 to 11) | 38.3 (25.8 to 54.7) | 10/2 | 1 (0 to 2) | 4.7 (2.2 to 8.6) | 5/8 | 0 (0 to 0) | 0.6 (0.2 to 1.5) | ||
| Men | 383/18 | 26 (24 to 27) | 21.7 (19.6 to 24.0) | 119/46 | 2 (1 to 3) | 2.6 (2.2 to 3.1) | 135/164 | 0 (−1 to 0) | 0.8 (0.7 to 1.0) | ||
| Kidney: | 130/8 | 7 (6 to 8) | 16.3 (13.6 to 19.4) | 57/21 | 1 (0 to 1) | 2.7 (2.0 to 3.5) | 108/77 | 0 (0 to 0) | 1.4 (1.2 to 1.7) | ||
| Women | 15/1 | 5 (3 to 6) | 19.2 (10.7 to 31.7) | 6/2 | 0 (0 to 1) | 2.8 (1.0 to 6.1) | 13/8 | 0 (0 to 1) | 1.7 (0.9 to 2.9) | ||
| Men | 115/7 | 8 (7 to 8) | 16.0 (13.2 to 19.2) | 51/19 | 1 (0 to 1) | 2.7 (2.0 to 3.5) | 95/69 | 0 (0 to 1) | 1.4 (1.1 to 1.7) | ||
| Renal pelvis* | 23/1 | 1 (1 to 2) | 17.2 (10.9 to 25.9) | 12/3 | 0 (0 to 0) | 3.5 (1.8 to 6.1) | 7/12 | 0 (0 to 0) | 0.6 (0.2 to 1.2) | ||
| Genitals: | |||||||||||
| Women | 80/5 | 24 (21 to 27) | 15.9 (12.6 to 19.8) | 19/14 | 1 (0 to 2) | 1.4 (0.8 to 2.2) | 42/50 | 0 (−1 to 1) | 0.8 (0.6 to 1.1) | ||
| Men | 3216/94 | 219 (215 to 222) | 34.0 (32.9 to 35.2) | 1039/248 | 21 (20 to 23) | 4.2 (3.9 to 4.5) | 1005/913 | 1 (0 to 2) | 1.1 (1.0 to 1.2) | ||
| Colorectum: | 273/63 | 12 (11 to 13) | 4.3 (3.8 to 4.9) | 170/165 | 0 (−1 to 1) | 1.0 (0.9 to 1.2) | 532/594 | 0 (−1 to 0) | 0.9 (0.8 to 1.0) | ||
| Women | 29/8 | 7 (5 to 9) | 3.5 (2.4 to 5.1) | 32/22 | 1 (0 to 3) | 1.4 (1.0 to 2.0) | 72/80 | 0 (−2 to 1) | 0.9 (0.7 to 1.1) | ||
| Men | 244/55 | 13 (12 to 14) | 4.5 (3.9 to 5.1) | 138/143 | 0 (−1 to 1) | 1.0 (0.8 to 1.1) | 460/514 | 0 (−1 to 0) | 0.9 (0.8 to 1.0) | ||
| Nervous system: | 46/10 | 2 (2 to 2) | 4.7 (3.4 to 6.2) | 29/26 | 0 (0 to 0) | 1.1 (0.7 to 1.6) | 114/97 | 0 (0 to 0) | 1.2 (1.0 to 1.4) | ||
| Women | 11/2 | 3 (2 to 4) | 6.2 (3.1 to 11.2) | 7/5 | 0 (0 to 1) | 1.4 (0.6 to 2.9) | 19/18 | 0 (−1 to 1) | 1.0 (0.6 to 1.6) | ||
| Men | 35/8 | 2 (1 to 2) | 4.3 (3.0 to 6.0) | 22/21 | 0 (0 to 0) | 1.0 (0.6 to 1.6) | 95/79 | 0 (0 to 0) | 1.2 (1.0 to 1.5) | ||
O/E=observed/expected; PY=person years; SIR=standardised incidence ratio.
*
Numbers were too few to separate by sex.